0
Skip to Content
NMD Pharma
Home
About
About NMD Pharma
Management team
Our team
Board
Founders
R&D
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Patients & Clinical Trials
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
News
Press releases
Events
Other news
Investors
Careers
Your career
Find your job
Contact
NMD Pharma
Home
About
About NMD Pharma
Management team
Our team
Board
Founders
R&D
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Patients & Clinical Trials
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
News
Press releases
Events
Other news
Investors
Careers
Your career
Find your job
Contact
Home
Folder: About
Back
About NMD Pharma
Management team
Our team
Board
Founders
Folder: R&D
Back
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Folder: Patients & Clinical Trials
Back
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
Folder: News
Back
Press releases
Events
Other news
Investors
Folder: Careers
Back
Your career
Find your job
Contact
Muscular chloride channel inhibition improves neuromuscular function</a>
Test-scientific Stine Krag Brunvold 3/11/19 Test-scientific Stine Krag Brunvold 3/11/19

Muscular chloride channel inhibition improves neuromuscular function

It all begins with an idea.

Read More

NMD PHARMA A/S, CVR No. 36899069

Cookie Policy Terms of Use Privacy Policy US Expanded Access Policy

Follow us
LinkedIn and X